Director William Snider Buys Over $103K in Harvard Bioscience Stock Post-Reverse Split

summarizeSummary

Director William Snider purchased $103,604 worth of Harvard Bioscience common stock in open market transactions, increasing his direct holdings following the company's recent reverse stock split and earnings report.

check_boxKey Events · Ownership and Investor Activity · HBIO

• Director's Open Market Purchase

  Director William Snider acquired 21,000 shares of common stock for a total value of $103,604 through open market purchases on March 16 and 17, 2026.

• Significant Investment Post-Reverse Split

  The purchases occurred immediately after the company's 1-for-10 reverse stock split on March 13, 2026, and a recent 10-K filing detailing a substantial net loss for FY2025, indicating conviction despite recent challenges.

• Increased Direct Holdings

  Following these transactions, Mr. Snider's direct holdings in Harvard Bioscience increased to 32,000 shares, which includes 11,000 restricted stock units adjusted for the reverse stock split.

auto_awesomeAnalysis · HBIO · Industrial Applications And Services

Director William Snider's open market purchase of $103,604 in Harvard Bioscience common stock is a notable signal of confidence, especially given the recent corporate developments. This transaction occurred just days after the company's 1-for-10 reverse stock split on March 13, 2026, and following a 10-K filing on the same day that reported a significant net loss for FY2025. The director's decision to increase his direct holdings to 32,000 shares, including restricted stock units, immediately after these events suggests a belief in the company's future despite recent financial challenges and the stock split.